An enzyme-linked immunosorbent assay (ELISA) was applied to a light protein, isolated from human breast cyst fluid (BCF) termed « gross cystic disease fluid protein - 15 Kda » (GCDFP-15), a potential differentiation marker in in vitro human breast cancer studies. The detection limits of this procedure, performed in microtiter plates, were 0.5 to 250 ng/well corresponding to 10 ng/ml to 5 ng/ml of sample or antigen solution. Possible cross-reaction with various antigens, especially those found in culture media, were investigated. The correlation coefficient between enzymoassay and radioimmunoassay was 0.978. The results showed that quantification of GCDFP-15 by ELISA is a specific and highly sensitive method. This procedure may be of interest in in vitro studies on the functional differentiation of breast cancer cells.
Get full access to this article
View all access options for this article.
References
1.
DixonJ.M., LumsdenA.B., MillerW.R.: The relationship of cyst type to risk factors for breast cancer and the subsequent development of breast cancer in patients with breast cystic disease.Eur. J. Cancer Clin. Oncol., 21: 1047–1050, 1985.
2.
HaagensenC.D., BodianC., HaagensenD.E.Jr.: Breast Carcinoma: Risk and Detection.W.B. Saunders, Philadelphia, 1981.
3.
HaagensenD.E.Jr., MazoujianG., HolderW.O., KisterS.J., WellsS.A.: Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients.Ann. Surg., 185: 279–285, 1977.
4.
HaagensenD.E.Jr., KisterS.J., PanickJ., GiannolaJ., HansenH.J., WellsS.A.Jr.: Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma.Cancer, 42: 1646–1652, 1978.
5.
HaagensenD.E.Jr., MazoujianG., DilleyW.G., PedersonC.E., KisterS.J., WellsS.A.: Breast gross cystic disease fluid analysis. I. Isolation and radioimmunoassay for a major component protein.J. Natl. Cancer Inst., 62: 239–247, 1979.
6.
HaagensenD.E.Jr., BarryW.F.Jr., McCookT.A., GiannolaJ., AmmirataS., WellsS.A.Jr.: The value of serial plasma levels of carcinoembryonic antigen and gross cystic disease fluid protein in patients with breast carcinoma and osseous metastases.Ann. Surg., 191: 599–603, 1980.
7.
HaagensenD.E.Jr., MazoujianG.: Relationship of glycoproteins in human breast cystic disease fluid to breast carcinoma. In: Endocrinology of Cystic Breast Disease.AngeliA., BradlowH.L., DogliottiL. (Eds.), pp. 149–168, Raven Press, New York, 1983.
8.
LewinsonE., LyonsL.: Relationship between breast disease and cancer.Arch. Surg., 66: 94–96, 1953.
9.
MacMahonB., ColeP., BrownJ.: Biology of human breast cancer: a review.J. Natl. Cancer Inst., 50: 21–43, 1973.
10.
MazoujianG., PinkusG.S., DavisS., HaagensenD.E.Jr.: Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features.Am. J. Pathol., 110: 105–112, 1983.
11.
OsborneK.: Effects of antiestrogens and estrogens on proliferation of human breast cancer cells: in vitro and in vivo models. In: Progress in Cancer Research and Therapy.BrescianiF., KingR.J.B., LippmanM.E., NamerM., RaynaudJ.P. (Eds.), vol. 31, pp. 187–191, Raven Press, New York, 1984.
12.
PageD.L., Zander-ZuaagR., RogersL.W., WilliamsL.T., WalkerW.E., HartmannW.H.: Relationship between component parts of fibrocystic disease complex and breast cancer.J. Natl. Cancer Inst., 61: 1055–1063, 1978.
13.
RochefortH., ChalbosD.: Progestin specific markers in human cell lines: biological and pharmacological applications.Mol. Cell. Endocrinol., 36: 3–10, 1984.
14.
SutherlandR.L., MurphyL.C., HallR.E., ReddelR.R., WattsC.K.W., TaylorI.W.: Effects of antiestrogens on human breast cancer cells in vitro. Interactions with high affinity intracellular binding sites and effects on cell proliferation kinetics. In: Progress in Cancer Research and Therapy.BrescianiF., KingR.J.B., LippmanM.E., NamerM., RaynaudJ.P. (Eds.), vol. 31, pp. 193–212, Raven Press, New York, 1984.
15.
VaitukaitisJ., RobbinsJ.B., NieschlagE., RossG.T.: A method for producing specific antisera with small doses of immunogen.J. Clin. Endocrinol., 33: 988–991, 1971.
16.
VandewalleB., HornezL., VenninP., PeyratJ.P., LefebvreJ.: Further characterization of the light breast cyst fluid protein, GCDFP-15.Biochimie, 68: 649–656, 1986.
17.
VandewalleB., Collyn-D'HoogheM., SavaryJ.B., VilainM.O., PeyratJ.P., DeminattiM., Delobelle-DeroideA., LefebvreJ.: Establishment and characterization of a new cell line (VHB-1) derived from a primary breast carcinoma.J. Cancer Res. Clin. Oncol., 113: 550–558, 1987.
18.
VeronesiU., PizzocaroG.: Breast cancer in women subject to cystic disease of the breast.Surg. Gynecol. Obstet., 126: 529–534, 1977.
19.
WestleyB., RochefortH.: Estradiol-induced proteins in the MCF7 human breast cancer cell line.Biochem. Biophys. Res. Commun., 90: 410–416, 1979.
20.
ZangerleP.F., ColletteJ., HendrickJ.C., MillerW.B., FranchimontP.: Milk proteins and breast cancer. In: Markers for Diagnosis and Monitoring of Human Cancer.ColnaghiM.I., BuraggiG.L., GhioneM. (Eds.), vol. 46, pp. 35–49, Academic Press, New York, 1982.
